Search research articles
Contact Us
Filters
Showing results (481-490 of 514) with videos related to
Page
of 52
Sort By:
Journal of Integrative Plant Biology
|
October 30, 2025
NUDIX hydrolases target specific inositol pyrophosphates and regulate phosphate homeostasis and bacterial pathogen susceptibility in Arabidopsis
Robin Schneider, Klea Lami, Isabel Prucker, et al.
Hepatology (Baltimore, Md.)
|
March 21, 2022
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study
Antonio D'Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, et al.
Hepatology Communications
|
October 27, 2023
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
Vincent Joerg, Bernhard Scheiner, Antonio D Alessio, et al.
Oncoimmunology
|
August 16, 2019
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
M Moehler, J Heo, H C Lee, et al.
Hepatology Communications
|
November 4, 2024
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort
Tiago de Castro, Sabrina Welland, Leonie Jochheim, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 23, 2022
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D'Alessio, et al.
Journal of Hepatology
|
October 14, 2021
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score
Bernhard Scheiner, Katharina Pomej, Martha M Kirstein, et al.
Journal of Hepatocellular Carcinoma
|
April 9, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab
Bernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, et al.
Hepatology (Baltimore, Md.)
|
October 21, 2019
Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers
Felix Stickel, Philipp Lutz, Stephan Buch, et al.
JHEP Reports : Innovation in Hepatology
|
January 26, 2024
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
Lorenz Balcar, Bernhard Scheiner, Claudia Angela Maria Fulgenzi, et al.
Page
of 52
Search research articles
Search
Showing results (481-490 of 514) with videos related to
Sort By:
Page
of 52
Journal of Integrative Plant Biology
|
October 30, 2025
NUDIX hydrolases target specific inositol pyrophosphates and regulate phosphate homeostasis and bacterial pathogen susceptibility in Arabidopsis
Robin Schneider, Klea Lami, Isabel Prucker, et al.
Hepatology (Baltimore, Md.)
|
March 21, 2022
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study
Antonio D'Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, et al.
Hepatology Communications
|
October 27, 2023
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
Vincent Joerg, Bernhard Scheiner, Antonio D Alessio, et al.
Oncoimmunology
|
August 16, 2019
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
M Moehler, J Heo, H C Lee, et al.
Hepatology Communications
|
November 4, 2024
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort
Tiago de Castro, Sabrina Welland, Leonie Jochheim, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 23, 2022
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D'Alessio, et al.
Journal of Hepatology
|
October 14, 2021
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score
Bernhard Scheiner, Katharina Pomej, Martha M Kirstein, et al.
Journal of Hepatocellular Carcinoma
|
April 9, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab
Bernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, et al.
Hepatology (Baltimore, Md.)
|
October 21, 2019
Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers
Felix Stickel, Philipp Lutz, Stephan Buch, et al.
JHEP Reports : Innovation in Hepatology
|
January 26, 2024
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
Lorenz Balcar, Bernhard Scheiner, Claudia Angela Maria Fulgenzi, et al.
Page
of 52